Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Yuanyuan
NCT04003246: Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer	Active, not recruiting	2	50	US	Thoracic RT and Durvalumab, Consolidative Durvalumab	University of Texas Southwestern Medical Center, AstraZeneca	Non Small Cell Lung Cancer, Lung Cancer Stage III	08/25	08/26
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors	Recruiting	1	350	US, RoW	IMP7068	Impact Therapeutics, Inc., Covance	Advanced Solid Tumors	04/23	08/23